肝移植患者术后感染发生率高，多重耐药鲍曼不动杆菌（MDRAB），尤其是碳青霉烯类耐药鲍曼不动杆菌（CRAB），严重威胁患者预后。本研究报道1例肝移植术后MDRAB重症感染病例。患者术后出现脓毒症、脓毒性休克和重症肺炎，初始多黏菌素、替加环素等联合方案效果欠佳。根据病原学和药敏结果，调整为舒巴坦-度洛巴坦+美罗培南+多黏菌素雾化吸入治疗。治疗后患者体温、炎症指标、氧合功能及影像学显著改善，微生物学培养转阴，且肝肾功能得到恢复。该病例提示，舒巴坦-度洛巴坦在肝移植术后MDRAB感染治疗中疗效显著、安全性良好，为临床提供了新的有效选择。

Post-transplant infections are common in liver transplant recipients, with multidrug-resistant Acinetobacter baumannii (MDRAB), especially carbapenem-resistant strains (CRAB), posing a major threat to prognosis. We report a case of severe MDRAB infection after liver transplantation. The patient developed sepsis, septic shock, and severe pneumonia, and showed poor response to initial combination therapy with polymyxin and tigecycline. Based on microbiological findings, the regimen was switched to sulbactam–durlobactam plus meropenem and nebulized polymyxin. The patient achieved rapid improvement in temperature, inflammatory markers, oxygenation, and imaging, with negative cultures and recovery of liver and renal function. This case highlights the favorable efficacy and safety of sulbactam–durlobactam in managing MDRAB infections after liver transplantation, providing a valuable therapeutic option for clinical practice.